Imidazole Scaffold Swap Delivers Selective, Oral CDK2 Inhibitor INCB127443
- An earlier pyrazole-based CDK2 inhibitor scaffold was computationally redesigned around an imidazole core to improve selectivity over CDK1.
- The new chemotype was optimized simultaneously for potency, CDK1/CDK2 selectivity, and physicochemical properties.
- This work yielded INCB127443, an orally bioavailable candidate with favorable CDK1 selectivity and a flat pharmacokinetic profile enabling sustained in vivo target coverage.
💡 Points
Swapping pyrazole for imidazole to fix CDK1 selectivity is a single-atom-position bet—when it works, it usually means the selectivity handle is a subtle H-bond vector difference in the near-identical ATP pockets, not a size mismatch, which is the harder kind to exploit on purpose. Imidazole is cheap, well-trodden SAR territory, and the flat PK is the real prize for sustained target coverage.
Discovery of INCB127443: A Potent and Orally Available Inhibitor of Cyclin-Dependent Kinase 2 ↗